How to Help Your Patients Save Money on Nevanac: A Provider's Guide to Savings Programs

Medication cost is one of the most significant and underappreciated barriers to post-operative compliance in cataract surgery care. Nevanac (nepafenac 0.1% ophthalmic suspension) carries a retail price of $329–$413 per 3mL bottle — and with no generic available, patients cannot simply switch to a cheaper equivalent at the pharmacy counter. This guide equips your practice with the tools and resources to proactively address Nevanac cost barriers and protect your patients' post-operative outcomes.

Why Medication Cost Matters for Post-Op Compliance

Non-adherence to post-operative eye drop regimens is associated with significantly worse surgical outcomes, including elevated rates of cystoid macular edema (CME), prolonged inflammation, and suboptimal visual acuity. Research consistently shows that cost is among the primary drivers of non-adherence — particularly for brand-name medications without generics.

Patients who can't afford Nevanac may:

Skip fills entirely — accepting the risk of unmanaged post-surgical inflammation

Ration drops (use fewer doses per day than prescribed)

Stop treatment before the 14-day post-op period is complete

Avoid disclosing cost concerns to the surgical team — hoping the issue resolves itself

Understanding Nevanac's Cost Landscape in 2026

Before you can connect patients with the right resource, it helps to understand the pricing environment:

Retail (no discount): $329–$413 per 3mL bottle

With GoodRx/SingleCare coupon: ~$323–$330 at participating pharmacies

Insurance copay (where covered): $60–$80 (approximately 80% of plans cover Nevanac; many require PA or step therapy)

Novartis Patient Assistance: $0 for qualifying uninsured/underinsured patients

Generic alternatives: $15–$200 depending on the agent (ketorolac, diclofenac, or bromfenac generics)

Tier 1: Patients with Insurance Coverage

For insured patients, the main barrier is prior authorization delay rather than absolute cost. Strategies for this group:

Initiate PA early: Submit the PA request at the time of the pre-operative appointment — not after the pharmacist rejects the claim

Use PA appeal language: For denials, document medical necessity — patient history of NSAID intolerance to alternatives, prior macular edema, or diabetes

Check if step therapy applies: Some plans require documentation that ketorolac or bromfenac was tried first; if your patient hasn't tried these, be prepared to explain clinical justification for starting with Nevanac

Suggest comparing GoodRx vs. insurance: In some cases, GoodRx prices may be lower than the insurance copay — encourage patients to check both

Tier 2: Uninsured and Underinsured Patients

For patients without adequate insurance, the following programs can eliminate or significantly reduce the cost of Nevanac:

Novartis Patient Assistance Foundation: Provides Nevanac at no cost. Phone: 1-800-277-2254. Eligibility typically requires lack of adequate insurance and income below certain thresholds. Applications can be submitted online or by phone, and physician documentation is typically required.

Prescription Hope: Provides medications at a flat $70/month rate through manufacturer assistance programs. Works best for patients who may not qualify directly for manufacturer programs. Not an insurance plan — a managed access service.

NeedyMeds.org: A database of patient assistance programs, discount cards, and free/low-cost clinics. Useful for staff searching for options across a patient's multiple medications.

GoodRx and SingleCare: Even for uninsured patients, GoodRx/SingleCare can reduce cost to ~$323–$330. This isn't as impactful as PAP programs, but it's immediately accessible without enrollment.

Tier 3: When Cost Cannot Be Resolved — Clinical Alternatives

When Nevanac's cost cannot be resolved through any program or insurance pathway, prescribing an alternative ophthalmic NSAID is clinically appropriate. Evidence supports the use of all FDA-approved ophthalmic NSAIDs for post-cataract inflammation:

Generic bromfenac ($80–$200, once daily): Best efficacy-to-dosing-frequency balance; once-daily compliance advantage; generic available

Generic ketorolac ($15–$50, 4x daily): Most affordable option; strong evidence base; preservative-free option (Acuvail 0.45%) for sensitive patients

Generic diclofenac ($20–$60, 4x daily): Affordable with generic availability; long track record; four-times-daily dosing may reduce compliance

Building a Cost-Access Protocol Into Your Practice

Consider implementing a structured pre-surgical medication access checklist at your practice:

At the pre-op consultation: Ask about insurance coverage and financial situation for eye drops

Send prescriptions 7–10 days before surgery: Allows time for PA, savings program enrollment, or alternative fills

Designate a staff member to manage PA requests and patient assistance applications

Provide patients with a written resource sheet: Include pharmacy phone numbers, GoodRx/SingleCare instructions, and patient assistance program contacts

Direct patients to medfinder: For patients who can't find Nevanac at a pharmacy, medfinder contacts local pharmacies on their behalf and reports availability by text

The Bottom Line

Medication cost barriers are preventable — but only with proactive systems. By identifying at-risk patients early, initiating insurance PA before the claim is rejected, connecting uninsured patients with manufacturer assistance, and having affordable alternatives ready, ophthalmology practices can dramatically reduce the rate of Nevanac non-compliance. For more on the access side of Nevanac, see How to Help Your Patients Find Nevanac in Stock: A Provider's Guide.